AAV-mediated gene transfer in the perinatal period results in expression of FVII at levels that protect against fatal spontaneous hemorrhage

Christopher Binny, Jenny McIntosh, Marco Della Peruta, Hanna Kymalainen, Edward G D Tuddenham, Suzanne M K Buckley, Simon N. Waddington, John H. McVey, Yunyu Spence, Christopher L. Morton, Adrian J. Thrasher, John T. Gray, Francis J. Castellino, Alice F Tarantal, Andrew M. Davidoff, Amit C. Nathwani

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

We explored adeno-associated viral vector (AAV)-mediated gene transfer in the perinatal period in animal models of severe congenital factor VII (FVII) deficiency, a disease associated with early postnatal life-threatening hemorrhage. In young adult mice with plasma FVII < 1% of normal, a single tail vein administration of AAV (1 × 10 13 vector genomes [vg]/kg) resulted in expression of murine FVII at 266% ± 34% of normal for ≥ 67 days, which mediated protection against fatal hemorrhage and significantly improved survival. Codon optimization of human FVII (hFVIIcoop) improved AAV transgene expression by 37-fold compared with the wild-type hFVII cDNA. In adult macaques, a single peripheral vein injection of 2 × 10 11 vg/kg of the hFVIIcoop AAV vector resulted in therapeutic levels of hFVII expression that were equivalent in males (10.7% ± 3.1%) and females (12.3% ± 0.8%). In utero delivery of this vector in the third trimester to fetal monkeys conferred expression of hFVII at birth of 20.4% ± 3.7%, with a gradual decline to > 1% by 7 weeks. Readministration of an alternative serotype at 12 months postnatal age increased hFVII levels to 165% ± 6.2% of normal, which remained at therapeutic levels for a further 28 weeks without toxicity. Thus, perinatal AAV-mediated gene transfer shows promise for disorders with onset of pathology early after birth.

Original languageEnglish (US)
Pages (from-to)957-966
Number of pages10
JournalBlood
Volume119
Issue number4
DOIs
StatePublished - Jan 26 2012

Fingerprint

Gene transfer
Factor VII
Factor VII Deficiency
Hemorrhage
Deficiency Diseases
Pathology
Genes
Toxicity
Young Adult
Animals
Animal Models
Parturition
Plasmas
Therapeutics
Serogroup

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Binny, C., McIntosh, J., Della Peruta, M., Kymalainen, H., Tuddenham, E. G. D., Buckley, S. M. K., ... Nathwani, A. C. (2012). AAV-mediated gene transfer in the perinatal period results in expression of FVII at levels that protect against fatal spontaneous hemorrhage. Blood, 119(4), 957-966. https://doi.org/10.1182/blood-2011-09-377630

AAV-mediated gene transfer in the perinatal period results in expression of FVII at levels that protect against fatal spontaneous hemorrhage. / Binny, Christopher; McIntosh, Jenny; Della Peruta, Marco; Kymalainen, Hanna; Tuddenham, Edward G D; Buckley, Suzanne M K; Waddington, Simon N.; McVey, John H.; Spence, Yunyu; Morton, Christopher L.; Thrasher, Adrian J.; Gray, John T.; Castellino, Francis J.; Tarantal, Alice F; Davidoff, Andrew M.; Nathwani, Amit C.

In: Blood, Vol. 119, No. 4, 26.01.2012, p. 957-966.

Research output: Contribution to journalArticle

Binny, C, McIntosh, J, Della Peruta, M, Kymalainen, H, Tuddenham, EGD, Buckley, SMK, Waddington, SN, McVey, JH, Spence, Y, Morton, CL, Thrasher, AJ, Gray, JT, Castellino, FJ, Tarantal, AF, Davidoff, AM & Nathwani, AC 2012, 'AAV-mediated gene transfer in the perinatal period results in expression of FVII at levels that protect against fatal spontaneous hemorrhage', Blood, vol. 119, no. 4, pp. 957-966. https://doi.org/10.1182/blood-2011-09-377630
Binny, Christopher ; McIntosh, Jenny ; Della Peruta, Marco ; Kymalainen, Hanna ; Tuddenham, Edward G D ; Buckley, Suzanne M K ; Waddington, Simon N. ; McVey, John H. ; Spence, Yunyu ; Morton, Christopher L. ; Thrasher, Adrian J. ; Gray, John T. ; Castellino, Francis J. ; Tarantal, Alice F ; Davidoff, Andrew M. ; Nathwani, Amit C. / AAV-mediated gene transfer in the perinatal period results in expression of FVII at levels that protect against fatal spontaneous hemorrhage. In: Blood. 2012 ; Vol. 119, No. 4. pp. 957-966.
@article{bd025dca582d40358fadee021d9a4498,
title = "AAV-mediated gene transfer in the perinatal period results in expression of FVII at levels that protect against fatal spontaneous hemorrhage",
abstract = "We explored adeno-associated viral vector (AAV)-mediated gene transfer in the perinatal period in animal models of severe congenital factor VII (FVII) deficiency, a disease associated with early postnatal life-threatening hemorrhage. In young adult mice with plasma FVII < 1{\%} of normal, a single tail vein administration of AAV (1 × 10 13 vector genomes [vg]/kg) resulted in expression of murine FVII at 266{\%} ± 34{\%} of normal for ≥ 67 days, which mediated protection against fatal hemorrhage and significantly improved survival. Codon optimization of human FVII (hFVIIcoop) improved AAV transgene expression by 37-fold compared with the wild-type hFVII cDNA. In adult macaques, a single peripheral vein injection of 2 × 10 11 vg/kg of the hFVIIcoop AAV vector resulted in therapeutic levels of hFVII expression that were equivalent in males (10.7{\%} ± 3.1{\%}) and females (12.3{\%} ± 0.8{\%}). In utero delivery of this vector in the third trimester to fetal monkeys conferred expression of hFVII at birth of 20.4{\%} ± 3.7{\%}, with a gradual decline to > 1{\%} by 7 weeks. Readministration of an alternative serotype at 12 months postnatal age increased hFVII levels to 165{\%} ± 6.2{\%} of normal, which remained at therapeutic levels for a further 28 weeks without toxicity. Thus, perinatal AAV-mediated gene transfer shows promise for disorders with onset of pathology early after birth.",
author = "Christopher Binny and Jenny McIntosh and {Della Peruta}, Marco and Hanna Kymalainen and Tuddenham, {Edward G D} and Buckley, {Suzanne M K} and Waddington, {Simon N.} and McVey, {John H.} and Yunyu Spence and Morton, {Christopher L.} and Thrasher, {Adrian J.} and Gray, {John T.} and Castellino, {Francis J.} and Tarantal, {Alice F} and Davidoff, {Andrew M.} and Nathwani, {Amit C.}",
year = "2012",
month = "1",
day = "26",
doi = "10.1182/blood-2011-09-377630",
language = "English (US)",
volume = "119",
pages = "957--966",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - AAV-mediated gene transfer in the perinatal period results in expression of FVII at levels that protect against fatal spontaneous hemorrhage

AU - Binny, Christopher

AU - McIntosh, Jenny

AU - Della Peruta, Marco

AU - Kymalainen, Hanna

AU - Tuddenham, Edward G D

AU - Buckley, Suzanne M K

AU - Waddington, Simon N.

AU - McVey, John H.

AU - Spence, Yunyu

AU - Morton, Christopher L.

AU - Thrasher, Adrian J.

AU - Gray, John T.

AU - Castellino, Francis J.

AU - Tarantal, Alice F

AU - Davidoff, Andrew M.

AU - Nathwani, Amit C.

PY - 2012/1/26

Y1 - 2012/1/26

N2 - We explored adeno-associated viral vector (AAV)-mediated gene transfer in the perinatal period in animal models of severe congenital factor VII (FVII) deficiency, a disease associated with early postnatal life-threatening hemorrhage. In young adult mice with plasma FVII < 1% of normal, a single tail vein administration of AAV (1 × 10 13 vector genomes [vg]/kg) resulted in expression of murine FVII at 266% ± 34% of normal for ≥ 67 days, which mediated protection against fatal hemorrhage and significantly improved survival. Codon optimization of human FVII (hFVIIcoop) improved AAV transgene expression by 37-fold compared with the wild-type hFVII cDNA. In adult macaques, a single peripheral vein injection of 2 × 10 11 vg/kg of the hFVIIcoop AAV vector resulted in therapeutic levels of hFVII expression that were equivalent in males (10.7% ± 3.1%) and females (12.3% ± 0.8%). In utero delivery of this vector in the third trimester to fetal monkeys conferred expression of hFVII at birth of 20.4% ± 3.7%, with a gradual decline to > 1% by 7 weeks. Readministration of an alternative serotype at 12 months postnatal age increased hFVII levels to 165% ± 6.2% of normal, which remained at therapeutic levels for a further 28 weeks without toxicity. Thus, perinatal AAV-mediated gene transfer shows promise for disorders with onset of pathology early after birth.

AB - We explored adeno-associated viral vector (AAV)-mediated gene transfer in the perinatal period in animal models of severe congenital factor VII (FVII) deficiency, a disease associated with early postnatal life-threatening hemorrhage. In young adult mice with plasma FVII < 1% of normal, a single tail vein administration of AAV (1 × 10 13 vector genomes [vg]/kg) resulted in expression of murine FVII at 266% ± 34% of normal for ≥ 67 days, which mediated protection against fatal hemorrhage and significantly improved survival. Codon optimization of human FVII (hFVIIcoop) improved AAV transgene expression by 37-fold compared with the wild-type hFVII cDNA. In adult macaques, a single peripheral vein injection of 2 × 10 11 vg/kg of the hFVIIcoop AAV vector resulted in therapeutic levels of hFVII expression that were equivalent in males (10.7% ± 3.1%) and females (12.3% ± 0.8%). In utero delivery of this vector in the third trimester to fetal monkeys conferred expression of hFVII at birth of 20.4% ± 3.7%, with a gradual decline to > 1% by 7 weeks. Readministration of an alternative serotype at 12 months postnatal age increased hFVII levels to 165% ± 6.2% of normal, which remained at therapeutic levels for a further 28 weeks without toxicity. Thus, perinatal AAV-mediated gene transfer shows promise for disorders with onset of pathology early after birth.

UR - http://www.scopus.com/inward/record.url?scp=84856296022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856296022&partnerID=8YFLogxK

U2 - 10.1182/blood-2011-09-377630

DO - 10.1182/blood-2011-09-377630

M3 - Article

VL - 119

SP - 957

EP - 966

JO - Blood

JF - Blood

SN - 0006-4971

IS - 4

ER -